The advantages of PD1 activating chimeric receptor (PD1-ACR) engineered lymphocytes for PDL1(+) cancer therapy.Xiaolong Tang, Yong Liang, Jingjing Dai et al.|PubMed|2015Cited by 22
A third dose of inactivated SARS-CoV-2 vaccine induces robust antibody responses in people with inadequate response to two-dose vaccinationTaicheng Zhou, Zijie Zhang, Tianpei Shi et al.|National Science Review|2022Cited by 18